Home - Investor Relations Home
Investor Relations
CBPO Investor Presentation_2014 08 21

(2.3 MB)

2013 Annual Report

(8.7 MB)

China Biologic Products,Inc.

Corporate Profile

Overview  |  Management Team

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Founded in 2002 and headquartered in Beijing, China Biologic manufactures over 20 plasma-based products in three major classes (Human Albumin, Immunoglobulin, and Coagulation Factor) through its majority-owned subsidiaries, Shandong Taibang and Guizhou Taibang. The company also has an equity investment in Xi’an Huitian Blood Products Co., Ltd. The Company sells its products directly to over 1,000 hospitals and other healthcare facilities in China… More >> 

Upcoming Events
Key Contact

Ming Yin

Senior Vice President

China Biologic Products, Inc.    


Bill Zima

ICR Inc.